GLP-1 Receptor Agonists Modulate Vascular Biology, Suppressing Atherosclerosis in Type 2 Diabetes

Atherosclerosis is a progressive, chronic metabolic disorder characterized by endothelial dysfunction, inflammation, oxidative stress, and plaque remodeling, all significantly amplified in type 2 diabetes. Current standard-of-care often focuses on glycemic control and lipid management, yet residual cardiovascular risk remains high. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for glycemic control, have emerged as promising agents due to their pleiotropic effects on vascular biology, offering a potential avenue to directly address the underlying mechanisms of atherosclerosis in this vulnerable population.

This comprehensive review synthesizes current evidence regarding the role of GLP-1RAs in type 2 diabetes-associated atherosclerosis. It systematically examines key mechanistic domains, including endothelial dysfunction, inflammatory signaling, oxidative stress pathways, plaque biology, extracellular matrix remodeling, and immune-cell modulation. The review also explores emerging biomarker platforms, such as microRNA profiling, high-throughput proteomic and lipidomic signatures, and advanced imaging approaches like MRI-visible nano-GLP-1RA formulations, to highlight novel tools for monitoring molecular and spatial drug effects in vivo.

GLP-1RAs exert multifaceted anti-atherosclerotic effects. They significantly reduce circulating inflammatory mediators and suppress NLRP3 inflammasome activity, thereby limiting the initiation of vascular injury. Furthermore, GLP-1RAs lower oxidized LDL levels, a critical factor in plaque formation. At the endothelial level, they enhance nitric oxide (NO) availability, which is crucial for vascular relaxation, while simultaneously decreasing NOX-derived oxidative stress and reducing adhesion molecule expression, collectively improving vascular function. Within atherosclerotic plaques, GLP-1RA signaling alters macrophage behavior, promoting cholesterol efflux and modulating metalloproteinase activity, suggesting beneficial effects on plaque composition and stability. > These integrated effects span systemic immunometabolism and direct plaque biology, positioning GLP-1RAs as modulators of atherosclerotic disease beyond their primary role in glycemic control. Emerging omics technologies and advanced imaging provide novel tools to monitor these molecular and spatial drug effects.